The decision has been taken on the directives of the Chief Executive Officer of the National Medicines Regulatory Authority (NMRA).
Any individual who contravenes these directives shall be triable under section 131 of National Medicines Regulatory Authority Act No. 05 of 2015, further said the NMRA issuing a press release.